Anti-obesity agents

New Research on Liver Diseases and Conditions Reveals Promise of Glucagon-Like Peptide-1 Receptor Agonists

Investigators at Rutgers University - The State University of New Jersey have conducted new research on liver diseases and conditions, highlighting the potential of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in managing metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH). The study, published in Clinics

Anti-obesity agents

WADA Collects Evidence on GLP-1 Weight Loss Drugs for Potential Ban

The World Anti-Doping Agency (WADA) is monitoring the use of GLP-1 weight loss drugs by athletes, particularly in endurance sports, which could lead to a ban before the 2028 Olympics in Los Angeles. This has sparked concerns that the Los Angeles Games might be remembered as the "Ozempic Olympics&

Anti-obesity agents

Free Weight-Loss Drugs for Scotland's Poorest Residents Spark Debate on Obesity Crisis

Thousands of Scotland's poorest residents are set to receive free weight-loss drugs as part of a multi-million-pound trial examining the effectiveness of reducing obesity-related health pressures on the NHS. The UK Government-funded study aims to provide 5,000 injections of Wegovy to individuals living in deprived communities, with

Anti-obesity agents

Free Weight-Loss Drugs for Scotland's Poorest Residents Spark Debate on Obesity Crisis

Anti-obesity agents

Free Weight-Loss Drugs for Scotland's Poorest Residents Spark Debate on Obesity Crisis

Anti-obesity agents

Free Weight-Loss Drugs for Scotland's Poorest Residents Spark Debate on Obesity Crisis

Anti-obesity agents

Novo Nordisk Outbids Pfizer for Metsera in $6 Billion Acquisition Bid

Danish pharmaceutical giant Novo Nordisk has announced an unsolicited bid to acquire obesity treatment maker Metsera, topping a previous offer from US rival Pfizer. The bid values the US biotech firm at $6 billion, with Novo Nordisk offering $56.50 per share in cash. This move comes after Pfizer'

American College of Surgeons

Weight Loss Drugs Gain Popularity Among Bariatric Surgery Patients

New research findings indicate a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling a shift in the management of obesity and Type 2 diabetes. The study, presented at the American College of Surgeons (ACS) Clinical Congress 2025, reveals a surge in

Anti-obesity agents

NHS Wales Pauses Rollout of Weight-Loss Drugs due to Capacity Concerns

NHS Wales has announced it will continue to restrict prescriptions of new weight-loss drugs due to concerns over the service's capacity to handle a surge in demand. The decision affects around 186,000 people eligible for tirzepatide, which has been approved for managing obesity by the National Institute

Anti-obesity agents

Novo Nordisk Aims for $1 Billion Sales with Wegovy in India

Novo Nordisk, the Danish drug giant, is aggressively expanding its presence in the Indian market with its blockbuster weight-loss drug Wegovy (semaglutide). The company aims to hit $1 billion (Rs 8,600 crore) in sales with Wegovy in five to seven years, making it a game-changer in the prescription brand

Anti-obesity agents

Semaglutide May Help Prevent Heart Attacks and Strokes in Overweight People with Heart Failure

Research suggests that a weight loss drug, semaglutide, which has been shown to reduce major adverse cardiac events such as heart attacks and strokes in obese or overweight people with cardiovascular disease, may also benefit those with heart failure. A new study found that within the group of people with

Anti-obesity agents

Semaglutide's Heart Benefits Extend to Heart Failure Patients, New Research Suggests

New research has shown that the weight loss drug semaglutide, marketed under the brand names Wegovy and Ozempic, may have significant heart benefits for people with heart failure. A team of researchers from the University of London's Institute of Cardiovascular Science analyzed data from 4,286 people with

See all